Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New chimpanzee-human chimeric monoclonal antibodies were developed, which specifically bind to Norovirus and have therapeutic and immunoprophylactic potential.
The number of mergers and acquisitions in the pharmaceutical industry has continued to rise, with oncology being a particularly active area and assets increasingly being acquired at earlier stages of their development.
The potential of nucleic-acid-based drugs to halt the production of disease-associated proteins or to promote the production of therapeutic proteins has spurred a string of recent deals.
After safety issues dashed hopes several years ago, calcitonin-gene related peptide has re-emerged as a prominent target, catalyzing deals and potentially reinvigorating the generic-dominated migraine market.
Since the days of Watson, Crick, and Franklin, DNA has hogged the limelight, overshadowing RNA. Recently, however, RNA has claimed center stage as a multi-talented player, dialing gene expression up or down and even altering the genome through gene editing
The HPS-1 proMastocyte (HPM) cell line, containing an HPS-1 mutation, is the first mast cell line shown to constitutively release fibrotic proteins. This cell line serves as a model to study early mast cell development or fibrosis, or as a tool to screen therapeutic compounds for pulmonary fibrosis.
Progress in tackling technical challenges in the development of bispecific antibodies and emerging opportunities in the red-hot immuno-oncology space have catalyzed a flurry of dealmaking activity for bispecific platform companies.
Scientists at NIAID have developed a method of treating or preventing atopic dermatitis via the topical application of selected probiotic strains of gram-negative Roseomonas mucosa bacteria.
Cognition Therapeutics, Inc. has a first-in-class, clinical-stage, highly brain-penetrant and orally bioavailable small molecule designed to halt the initiation and progression of Alzheimer’s disease.
MeiraGTx is opening new frontiers in gene therapy by pioneering next-generation gene-regulation platforms to transform the application of gene therapy.
Over 80% of those who contract hepatitis B virus (HBV) recover from the disease, but some 350 million people worldwide are not able to control the virus and develop chronic infection that can seriously damage the liver — over 750,000 people die from complications every year.
The clinical-stage biotechnology company has pioneered the development of 3D spherical nucleic acids to treat a broad range of inflammatory disorders affecting multiple organs in the body.
Building on success in the oncology field, Astex Pharmaceuticals is applying its fragment based drug discovery (FBDD) platform to new neurodegenerative disease targets.
By overcoming formulation challenges and applying its controlled-release delivery systems, Intellipharmaceutics is creating new options for pain therapies.
The potential of gene silencing via RNAi has long been recognized, and innovations in the delivery of RNAi therapeutics by Dicerna Pharmaceuticals have enabled potent, long-acting gene silencing with a single subcutaneous injection for liver-associated diseases.
BioPact’s MGMR (Medical Grade Molecular Rebar) offers a safe and scalable nanoparticle platform for controlled and targeted delivery of a wide range of therapeutics.